Summary
Currently, expected 10-year first graft survival rates for kidneys from HLA-identical sibling, 1-haplotype-matched relative, and cadaver donors are 74, 51, and 40%, respectively. Histocompatibility, immunological conditioning with blood products, and immunosuppression with glucocorticoids, azathioprine, cyclosporin, and the antithymocyte (antilymphocyte) antibody preparations have been significant factors in the gradual improvement of kidney graft survival rates.
Nearly all immunosuppression regimens are cyclospprin-based. Antithymocyte antibody induction therapy with delayed administration of cyclosporin is widely practised to avoid cyclosporin nephrotoxicity while the kidney graft is recovering from preservation injury. Late cyclosporin withdrawal results in inferior cadaver kidney transplant survival rates. Rejection crises usually respond to high dose glucocorticoid therapy. Glucocorticoid-resistant rejection usually responds to treatment with antithymocyte antibody. FK-506 is a promising new immunosuppressant that has properties similar to cyclosporin. Prophylaxis against viral, bacterial and fungal infections is necessary to reduce the morbidity of immunosuppression. The incidence of malignant conditions associated with viral infections is significantly increased with immunosuppression.
New immunopharmacological agents and advances in genetic procedures may allow the induction of specific transplantation tolerance and successful xenotransplantation within the next decade.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Alexandre GPJ, Squifflet JP, DeBruyere M, Latinne D, Reding R, et al. Present experiences in a series of 26 ABO-incompatible living donor renal allografts. Transplantation Proceedings 19: 4538–4542, 1987
Barry JM, Shively N, Hubert B, Hefty T, Norman DJ, et al. Significance of delayed graft function in cyclosporine-treated recipients of cadaver kidney transplants. Transplantation 45: 347–349. 1988
Belitsky P, MacDonald AS, Cohen AD, Crocker J, Hirsch D, et al. Comparison of antilymphocyte globulin and continuous IV cyclosporine A as induction immunosuppression for cadaver kidney transplants: a prospective randomized study. Transplantation Proceedings 23: 999–1000, 1991
Beysens AJ, Wijnen RMH, Beuman GH, van der Heyden J, Kootstra G, et al. FK 506: Monitoring in plasma or in whole blood? Transplantation Proceedings 23: 2745–2747, 19
Brinker KR, Dickerman RM, Gonwa TA, Hall AR, Langley JW, et al. A randomized trial comparing double-drug and triple-drug therapy in primary cadaveric renal transplants. Transplantation 50: 43–49, 1990
Bry W, Warvariv V, Bohannon L, Feduska N, Staube G, et al. Cadaveric renal transplantation without prophylactic prednisone therapy. Transplantation Proceedings 23: 885–994, 1991
Calne RY. Immunosuppression for organ grafting. Transplantation Proceedings 23: 2175–2177, 1991
Calne RY, Rolles K, White DJG, Thiru S, Evans DB, et al. Cyclosporin A initially as the only immunosuppressant in 34 recipients of cadaveric organs: 32 kidneys, 2 pancreases, and 2 livers. Lancet 2: 1033–1036, 1979
Caralps A. History of immunosuppression in kidney transplantation. Transplantation Proceedings 20: 3–4, 1988
Castelao AM, Sabate I, Grino JM, Gil-Vernet S, Andres E, et al. Cyclosporine-drug interactions. Transplantation Proceedings 20: 66–69, 1988
Chatenaud L, Legendre C, Ferran C, Bach JF, Kreis, H. Corticosteroid inhibition of the OKT3-induced cytokine-related syndrome-dosage and kinetics prerequisites. Transplantation 51: 334–338, 1991
Consensus Document: Hawk’s Cay meeting on therapeutic drug monitoring of cyclosporine. Transplantation Proceedings 22: 1357–1361, 1990
Cosimi AB, Colvin RB, Goldstein G, et al. Treatment of acute allograft rejection with OKT3 monoclonal antibody. Transplantation 32: 535–539, 1981
Dallman MJ, Morris PJ. The immunology of rejection. In Morris (Ed.) Kidney transplantation: principles and practice, 3rd ed., pp. 15–36, WB Saunders, Philadelphia, 1988
First MR. Transplantation in the nineties. Transplantation 53: 1–11, 1992
Freedman BI, Tuttle AB, Lorentz WB, Browning MC, Meridith JH, et al. Conversion from cyclosporine: status after five years. Transplantation Proceedings 23: 1020–1022, 1991
Frey DJ, Matas AJ, Gillingham KJ, Canafax D, Payne WD, et al. MALG vs. OKT3 following renal transplantation: a randomized prospective trial. Transplantation Proceedings 23: 1048–1049, 1991
Goto T, Kino T, Hatanaka H, Okuhara M, Kohsaka M, et al. FK 506: historical perspectives. Transplantation Proceedings 23: 2713–2717, 1991
Greger B, Reis HJ, Meliert J, Schareck WD, Müller GH, et al. Rejection treatment by polyclonal antibodies in kidney transplantation: reliable therapy without severe side effects. Transplantation Proceedings 20 (Suppl. 6): 9–11, 1988
Griffin PJA, Salaman JR. Long-term results of cyclosporine monotherapy in kidney transplantation. Transplantation Proceedings 23: 992–993, 1991
Grino JM, Alsina J, Sabater R, Castelao AM, Gil-Vernet S, et al. Antilymphoblast globulin, cyclosporine and steroids in Cadaverci renal transplantation. Transplantation 49: 1114–1117, 1990
Gulanikar AC, Sungertekin U, MacDonald AS, Belitsky P, Bitter-Suermann H, et al. Sequential discontinuation of azathioprine and prednisone in renal transplantaion. Transplantation Proceedings 23: 2226–2227, 1991
Hall BM. Cells mediating allograft rejection. Transplantation, 51: 1141–1151, 1991
Hamilton B. Kidney transplantation: a history. In Morris (Ed.) Kidney transplantation: principles and practice, pp. 1–11, WB Saunders, Philadelphia, 1988
Hanto DW, Jendrisak MD, McCullough CS, So SKS, Marsh JW, et al. A prospective randomized comparison of prophylactic ALG and OKT3 in cadaver kidney allograft recipients. Transplantation Proceedings 23: 1050–1051, 1991
Hiesse C, Neyrat N, Deglise-Favre A, Lantz O, Bensadoun H, et al. Randomized prospective trial of elective cyclosporine withdrawal from triple therapy at six months after cadaveric renal transplantation. Transplantation Proceedings 23: 987–989, 1991
Jain AB, Buckles JAC, Adu D, Michael J, Mackintosh P, et al. Long-term results of cyclosporine in cadaveric renal transplantation from a single center. Transplantation Proceedings 20 (Suppl. 3): 82–85, 1988
Kahan BD. Cyclosporin. New England Journal of Medicine 321: 1725–1738, 1989
Kobayashi M, Tamura K, Katayama N, Nakamura K, Nagase K, et al. FK 506 assay past and present — characteristics of FK 506 ELISA. Transplantation Proceedings 23: 2725–2729, 1991
Kreis H, Legendre C, Chatenoud L. OKT3 in organ transplantation. Transplantation Reviews 5: 181–199, 1991
Krensky AM, Weiss A, Crabtree G, Davis MM, Paraham P. Tlymphocyte-antigen interactions in transplant rejection. New England Journal of Medicine 322: 510–517, 1990
Land W. For the European multicentre trial group. Cyclosporine in cadaveric renal transplantation: five-year follow-up results of the European multicenter trial. Transplantation Proceedings 20 (Suppl. 3): 73–77, 1988
Leichtman AB, Strom TB. Therapeutic approach to renal transplantation: triple therapy and beyond. Transplantation Proceedings 20: 1–6, 1988
Lemaire M, Fahr A, Maurer G. Pharmacokinetics of cyclosporine: inter- and intra-individual variations and metabolic pathways. Transplantation Proceedings 22: 1110–1112, 1990
Maiorca R, Christinelli L, Brunori G, Setti G, Salerai B, et al. Prospective controlled trial of steroid withdrawal after six months in renal transplant recipients treated with cyclosporine. Transplantation Proceedings 20 (Suppl. 3): 121–125, 1988
MacDonald AS, Daloze P, Dandavino R, Jindal S, Bear L, et al. A randomized study of cyclosporine with and without prednisone in renal allograft recipients. Transplant Proceedings 19: 1865–1866, 1987
Monaco AP. Renal Prophylaxis with orthoclone OKT3 in the United States. Transplantation Proceedings 21 (Suppl. 2): 7–13, 1989
Morris PJ. Cyclosporine. In Morris (Ed.) Kidney transplantation: principles and practice, pp. 285–317, WB Saunders, Philadelphia, 1988
Murray JE. Sir Roy Calne, surgeon and friend. Transplantation Proceedings 23: 2173–2174, 1991
Najarian JS, Matas AJ. The present and future of kidney transplantation. Transplantation Proceedings 23: 2075–2082, 1991
Norman DJ, Barry JM, Bennett WM, Munson JL, Meyer M, et al. OKT3 for induction immunosuppression in renal transplantation: a comparative study of high versus low doses. Transplantation Proceedings 23: 1052–1054, 1991
Norman DJ, Barry JM, Funnell B, Hennel K, Goldstein G. OKT3 for treatment of acute and steroid-and-ATG-resistant acute rejection in renal allograft transplantation. Transplantation Proceedings 17: 2744–2747, 1985
Opelz G. Comparison of immunosuppressive protocols in renal transplantation: a multi-center view. Transplantation Proceedings 20: 31–36, 1988
Opelz G. Collaborative Transplant Study. Collaborative Transplant Study Newsletter 3: 1–5, 15 May, 1990a
Opelz G. Collaborative Transplant Study. Collaborative Transplant Study Newsletter 4: 1–3, 18 July, 1990b
Opelz G, Schwarz V, Engelmann A, Back D, Wilk M, et al. Long-term impact of HLA matching on kidney graft survival in cyclosporine-treated recipients. Transplantation Proceedings 23: 373–375, 1991
Ortho Multicenter Transplant Study Group. A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. New England Journal of Medicine 313: 337–342, 1985
Penn I. The changing pattern of posttransplant malignancies. Transplantation Proceedings 23: 1101–1103, 1991
Salaman JR, Griffin PJA, Ross WB, Williams JD. A controlled trial of triple therapy in renal transplantation. Transplantation Proceedings 19: 1935–1936, 1987
Sandimmune (Cyclosporine, USP). In Schumacher (Ed.) Physicians Desk Reference, 46th edn, pp. 2024–2027, Medical Economics Data, Montvale, NJ, 1992
Schleibner S, Schneeberger H, Hillebrand G, Illner WD, Krumme D, et al. Cyclosporine monotherapy — an ideal long-term immunosuppression? Transplantation Proceedings 22: 1695–1696, 1990
Shapiro R, Jordan M, Scantlebury V, Fung J, Jensen C, et al. FK 506 in clinical kidney transplantation. Transplantation Proceedings 23: 3065–3067, 1991
Sheil AGR, Disney APS, Mathew TH, Amiss N, Excell L. Cancer development in cadaveric donor renal allograft recipients treated with azathioprine (AZA) or cyclosporine (CyA) or AZA/CyA. Transplantation Proceedings 23: 1111–1112, 1991
Simmons RL, Migliori RJ. Infection prophylaxis after successful organ transplantation. Transplantation Proceedings 20 (Suppl. 8): 7–11, 1988
Slapak M, Digard N, Wise M, Setakis N. Triple therapy. Transplantation Proceedings 23: 2186–2188, 1991
Slapak M, Geogagen T, Digard N, Ahmed K, Sharman VL, et al. The use of low-dose cyclosporine in combination with azathioprine and steroids in renal transplantation. Transplantation Proceedings 17: 1222–1226, 1985
Sommer BG, Fergusson RM. The immediate post-transplant adjunct protocols combined with maintenance cyclosporine. Transplantation Proceedings 17: 1235–1235, 1985
Stiller CR, Opelz G. Should cyclosporine be continued indefinitely? Transplantation Proceedings 23: 36–40, 1991
Strom TB. Immunosuppressive treatments that thwart transplant rejection. Clinical Aspects of Autoimmunity 4: 8–19, 1990
Tarantino A, Aroldi A, Stucchi L, Montagnino G, Mascaretti L, et al. A randomized prospective trial comparing cyclosporine monotherapy with triple drug therapy in renal transplantation. Transplantation 52: 53–57, 1991
Tellis A, Matas AJ, Quinn TA, Glicklich D, Weiss RJ, et al. Antilymphoblast globulin treatment of steroid-resistant rejection in Cyclosporine-immunosuppressed renal transplant recipients. Transplantation Proceedings 19: 1892, 1987
Todd PA, Brogden RN. Muromonab CD3. A review of its pharmacology and therapeutic potential. Drugs 37: 871–899, 1989
Venkataraman ANR, Jain A, Warty VS, Abu-Elmagd K, Alessiani M, et al. Pharmacokinetics of FK 506 in transplant patients. Transplantation Proceedings 23: 2736–2740, 1991
Walker RG, d’Apice AJF. Azathioprine and steroids. In Morris (Ed.) Kidney transplantation: principles and practice, 3rd ed., pp. 319–341, WB Saunders, Philadelphia, 1988
Wenger R. Synthesis of cyclosporine and analogues: structure, activity, relationships of new cyclosporine derivatives. Transplantation Proceedings 15 (Suppl. 1): 2230–2241, 1983
Widmer U, Frei D, Keusch G, Burger HR, Largiader F, et al. OKT3 treatment of steroid- and/or anti-thymocyte globulin-resistant renal allograft rejection occurring on triple baseline immunosuppression including cyclosporine A. Transplantation Proceedings 20: 90–95, 1988
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barry, J.M. Immunosuppressive Drugs in Renal Transplantation. Drugs 44, 554–566 (1992). https://doi.org/10.2165/00003495-199244040-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199244040-00003